World Cancer Congress 2008

Hits:4420   Date: 12/14/2007

Time: June 12-17,2008
Venue: Everbright Convention & Exhibition Center
City: Shanghai, China
Website: www.bitlifesciences.com/cancer2008

Program Committee:

Chair
Jianren Gu, Ph.D., Chinese Academy of Engineering

Executive Chair
Xiaodan Mei, Ph.D., World High Technology Society

Scientific Advisor Board
Peter Vogt, Ph.D., The Member of the National Academy of Sciences, USA
Guofan Hong, Ph.D., Member of Chinese Academy of Sciences
Xinyuan Liu, Ph.D., Member of Chinese Academy of Sciences
Iwao Ojima, Ph.D., State University of New York at Stony Brook, USA
Ronald Breslow, Ph.D., Columbia University, USA
Samir N. Khleif, Ph.D., Senior Investigator, National Cancer Institute, USA
Moshe Szyf, Ph.D., McGill University, Canada
Alberto A. Gabizon, Ph.D., Professor and Chairman, Oncology Institute Shaare Zedek MC, and Hebrew University-School of Medicine, Israel
Asad Umar, Chief, Ph.D., Gastrointestinal and Other Cancers Research Group Division of Cancer Prevention National Cancer Institute, USA
Daniel Benchimol, Ph.D., The Dean, Nice Medical School, and as professor of general surgery and head of the department of general surgery and digestive oncology of Nice University Hospital, France
Christophe Louvet, Ph.D., Professor of Medicine, Deputy Director of the Oncology Department, Saint Antoine Hospital and University, France
Jean-Marie DANGOU, Ph.D., International Civil Servant, WHO, USA
Deborah Brennan, Ph.D., Assistant Chancellor, University of California, San Francisco, USA
B. Fervers, Director, Ph.D., SOR-FNCLCC, Centre Léon Bérard, France
Fernando Vidal-Vanaclocha, Ph.D., co-founder and officer of the International Cancer Microenvironment Society, and member of the Tumor Microenvironment Study Group of the AACR, Dept. Cell Biology and Histology Basque Country Univ School of Medicine, Spain
Mirza Shahid Arshad, Ph.D., "INTERNATIONAL SCIENTIST OF THE YEAR 2004" for outstanding contributions to medicine and surgery, Medical Officer, Basic Health Unit, Gurat Government of Punjab Health Department, Pakistan
Carrie Treadwell, Ph.D., Director of Research Programs, Brain Tumor Society, USA
Ahmad Mohammad Ragab Shalaby, Ph.D., Consultant of Histopathology, National Medical Institute, Egypt
Kamran Alimoghaddam, Ph.D., Associated Professor of Medical Sciences, Haematology, Oncology and BMT Research Centre of Tehran University of Medical Sciences, Shariati Hospital, Iran
Peiman Haddad, Ph.D., Associate Professor and Chairman, Dept. Radiation Oncology Cancer Institute, Tehran University of Medical Sciences, Iran
Jean-Pierre MARIE, Ph.D., Head of Hematology and Medical Oncology Department H?tel-Dieu Hospital, University Paris, France
Kenneth Bahk, Ph.D., Jennifer Viera Nanosphere, Inc., USA
Kai Q. Lao, Ph.D., Senior Scientist Group Leader, Exploratory Research Department, Applied Biosystems, USA
Michael T. Lotze, Ph.D., Director of Translational Research in the Molecular Medicine Institute, University of Pittsburgh Department of Surgery, USA
Mauro Ferrari, Ph.D., Professor and Director of Nanomedicine, Chairman, Department of Biomedical Engineering, Brown Institute of Molecular Medicine Chairman, Department of Biomedical Engineering The University of Texas Health Science Center, USA
Ulrich J?ger, Ph.D., Head of the Division of Hematology and Hemostaseology, The Medical University of Vienna, Austria
Nadir Arber, Ph.D., Professor of Medicine and Gastroenterology Head - Integrated Cancer Prevention Center, Tel Aviv Medical Center Prevention Center and Tel Aviv University, Israel
Jacques Pouyssegur, Ph.D., Director, Institute of Signaling, Developmental Biology and Cancer Research CNRS UMR 6543 Centre A. Lacassagne, Université de Nice-Sophia Antipolis, France
Henry Rodriguez, Ph.D., Director, Clinical Proteomic Technologies for Cancer Office of Technology and Industrial Relations Office of the Director National Cancer Institute, USA
VIRGíLIO SACCHINI, Ph.D., Associate Attending Surgeon, Memorial Sloan-Kettering Cancer Center, USA
Teru Hideshima, Ph.D., Principal Associate in Medicine, Jerome Lipper Myeloma Center Dana-Farber Cancer Institute, USA
Asad Umar, Chief, Ph.D., Gastrointestinal and Other Cancers Research Group Division of Cancer Prevention National Cancer Institute, USA
Viktor Umansky, Ph.D., Professor, Clinical Cooperation Unit Dermato-Oncology, German Cancer Research Center, Germany

Other members are to be invited…

Executive Committees
Colin Collins, Ph.D., UCSF Cancer Center, USA
Gary Wang, Ph.D., Abbott Laboratories, USA
Naijie Jing, Ph.D., Baylor College of Medicine, USA
Jochen Urthaler, Ph.D., Boehringer Ingelheim Austria GmbH, Austria
Naoki Muguruma, Ph.D., The University of Tokushima Graduate School, Japan
Dominik Wodarz, Ph.D., University of California, USA
Akira Nakagawara , Ph.D., Chiba Cancer Center Research Institute, Japan
Weimin Fan, Ph.D., Medical Uuniversity of South Carolina, USA
Adam McCluskey, Ph.D., University of Newcastle, Australia
Shu Zheng, Ph.D., President of Zhejiang Medical University and Director of Zhejiang University, Cancer Institute, China
Suzhan Zhang, Ph.D., the Associate Dean of Zhejiang University, Medical School and Current Director of the Cancer Institute and Zhejiang 2nd Affiliated Hospital, China
Weikang Tao, Ph.D., Merck Research Laboratories, USA
Maina Flavio, Ph.D., Developmental Biology Institute of Marseille, France
Yong Jia, Ph.D., Abbott Bioresearch Center, USA
Xin-jie Chu, Ph.D., Hoffmann-La Roche Inc., USA
Ming Li, Ph.D., Tulane University Health Sciences Center, USA
Jayaram Tagat, Ph.D., Schering-Plough Research Institute, USA
Jeff Simko, Ph.D., University of California, San Francisco, USA
Mary Waye, Ph.D., The Chinese University of Hong Kong, China
Robert J Hickey, Ph.D., Indiana University Cancer, USA

Local Program Coordinator
Annie Sun, Program Coordinator
Rebecca Zhan, Program Coordinator
Lunar Tian, Program Coordinator
Heyang Li, Program Coordinator
Kevin Li, Program Coordinator
Daisy Zhou, Program Coordinator

Key Dates

Important Deadlines
10 September 2007	Start date for online Early Bird registrations
10 September 2007	Start date for online/hard copy Abstract Submissions
16 December 2007	End date for online Early Bird registrations
14 January 2008	End date of BIT members' discounted registration rate
1 May 2008	End date for Abstract submissions
15 May 2008	End date of Abstract review process
30 May 2008	End date of Conference Registration Cancellation
20 May 2008	End date of Mailing of Abstract notification letters
25 May 2008	End date of requests for Letter of Invitation for visa application
30 May 2008	End date of guaranteed hotel reservation
1 June 2008	End date of pre-registration
5 June 2008	Hotel Accommodation Cancellation
5 June 2008	Deadline for cancellation of social program and tours
12 June 2008	Congress Opening Ceremony

Paper and Poster

Abstract information:

Abstract submission

For direct access to online abstract submission, click here

Call for abstracts
There will be opportunities for researchers to present their own work within the scope of the symposium, either as a proffered paper or a poster. Abstracts on cancer research pipeline within the scope of the symposium are invited. In order to be considered for presentation, abstracts need to be submitted online before or on April 30, 2008, according to the following instructions, click here. All abstracts will be reviewed by several independent experts. Notifications of acceptance or rejection, and scheduling information will be mailed to the submitting author within two weeks.

Topics for abstract submission
• Angiogenesis inhibitors
• Novel drug target
• Biomarker development and validation
• Combinations of targeted agents
• Drug design and discovery
• Drug profiles – preclinical
• Drug development methodology
• Downstream signaling pathways
• Immunological targets
• Molecular diagnosis and patient selection
• Phase 1 studies
• Phase 2 studies
• Phase 3 studies
• Regulatory issues
• Target identification and validation
• Tyrosine kinase inhibitors
• Tumor vaccines
• Molecular diagnosis, patient selection and prognosis
• Survival strategies and clinical trials
• Exercise, the mind and curative intent
• Patients, research and involvement
• Symptom management
• Living with cancer as a chronic illness
• End of life care
• Cancer Epidemiology
• Frontiers and Prospects in Cancer Prevention Research
• Improving Cancer Diagnostics
• Cancer in developing countries
• The Biology and Genetics of Cells and Organisms
• The Nature of Cancer
• Tumor Viruses
• Cellular Oncogenes
• Growth Factors and their Receptors
• Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer
• Tumor Suppressor Genes
• pRb and Control of the Cell Cycle Clock
• p53 and Apoptosis: Master Guardian and Executioner
• Eternal Life: Cell Immortalization and Tumorigenesis
• Multistep Tumorigenesis
• Maintenance of Genomic Integrity and the Development of Cancer
• Dialogue Replaces Monologue: Heterotypic Interactions and the Biology of Angiogenesis
• Moving Out: Invasion and Metastasis
• Crowd Control: Tumor Immunology and Immunotherapy
• The Rational Treatment of Cance
• Growth factor and Signalling pathways
• Structural biology
• Inflammation in cancer
• Immunological targets and mechanisms
• Methodology

Other topics
Abstract publication
All accepted abstracts will be published in the World Cancer Congress Proceedings at the meeting, and in a peer-reviewed scientific journal shortly after the meeting. Abstracts will not be released publicly prior to May 20, 2008.

Further information, should contact:
Annie Sun
Program Coordinator
E-mail: annie@bitlifesciences.com

Submission Guidelines

1. The organizers of World Cancer Congress invite abstracts within the scope of the meeting. Submitted abstracts will be reviewed by experts and be scheduled for oral or poster presentation during the congress if the topic is relevant and the quality of the data justifies its scheduling. Irrelevant or poor-quality abstracts may be rejected.

2. Abstracts can only be submitted online via the congress website. It is advisable to prepare the complete abstract text and any figures/tables before accessing online abstract submission.

3. Abstracts need to written in clear English, taking into account the specifications below (see also sample on the next page):
a. Maximum word count abstract title: 20 words.
b. Maximum word count abstract text: 350 words (adjust in case of tables./figures).
c. Abstract topic should be selected during the online submission process form the list of predefined topics to facilitate abstract review and scheduling.
d. A minimum of three specific keywords should be added during online submission for indexing of the abstract. Specific keywords are: name(s) of drug(s) investigated, molecular target molecule(s), disease(s) studied, biochemical or biological function(s) studied. Avoid the use of non-specific keywords, such as: angiogenesis, cell death, cancer, tumor, drug development, drug therapy. The World Cancer Congress reserve the rights to delete, edit, or add keywords to achieve uniformity throughout abstract publications.
e. Use International Nonproprietary Names (INN) or research codes to identify drugs throughout the abstract. Proprietary names may be used in the abstract text, not the abstract title, the first time the drug is mentioned there (put proprietary names between brackets).
f. The identity of a new, previously unpublished drug substance needs to be disclosed in the abstract, either by providing its struc-tural formula or its full chemical name.

4. Abstracts will be published exactly as submitted. No editing of abstract texts will be done. However, non-adherence to the above guidelines may be corrected (e.g. use of drug names, keywords) by the meeting organizers.

5. After submission, abstracts cannot be changed by the authors anymore. Should minor changes be necessary after submission, the submitting author should notify the World Cancer Congress Secretariat by email, describing exactly the nature of the change to be made. The World Cancer Congress organizers will then implement the change. In case of major changes, the authors should submit a revised abstract as an entirely new abstract and request the World Cancer Congress Secretariat to delete the original abstract. The addition of a co-author constitutes a major change.

6. After completion of the abstract review, the submitting author will receive scheduling information via email. Abstracts cannot be withdrawn after receipt of the scheduling information by the submitting author. The presenting author must be registered as a World Cancer Congress participant for final scheduling and publication of the abstract.

7. Accepted abstracts will be published in the World Cancer Congress Proceedings, and in a (supplement to a) medical journal. Abstracts will not be released publicly before May 20, 2008.

Click here for the abstract sample

Contact us

For Program and Speakers:
Annie Sun Organizing Committee of The World Cancer Congress 26 Gaoneng St., R401 Dalian Hightech Zone Dalian, LN 116025, China Tel: 0086-411-84799479 Fax: 0086-411-84799629 Email: annie@bitlifesciences.com
For Attendees and Media Partners:
Lunar Tian Organizing Committee of The World Cancer Congress 26 Gaoneng St., R401 Dalian Hightech Zone Dalian, LN 116025, China Tel: 0086-411-84799479 Fax: 0086-411-84799629 Email: lunar@bitlifesciences.com	or	Rebecca Zhan Organizing Committee of The World Cancer Congress 26 Gaoneng St., R401 Dalian Hightech Zone Dalian, LN 116025, China Tel: 0086-411-84799479 Fax: 0086-411-84799629 Email: rebecca@bitlifesciences.com